Passage Bio Stock Performance
| PASG Stock | USD 0.47 0.02 4.44% |
The company holds a Beta of 1.31, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Passage Bio will likely underperform. At this point, Passage Bio has a negative expected return of -0.32%. Please make sure to check Passage Bio's kurtosis, as well as the relationship between the day median price and relative strength index , to decide if Passage Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Passage Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
1 | Disposition of 230321 shares by Orbimed Advisors Llc of Passage Bio at 0.6 subject to Rule 16b-3 | 12/20/2024 |
2 | Acquisition by Lynx1 Capital Management Lp of 373645 shares of Passage Bio at 0.6451 subject to Rule 16b-3 | 12/27/2024 |
3 | Disposition of 19481 shares by Orbimed Advisors Llc of Passage Bio at 0.77 subject to Rule 16b-3 | 01/06/2025 |
4 | Is Passage Bio In A Good Position To Deliver On Growth Plans | 01/07/2025 |
5 | Disposition of 75007 shares by Orbimed Advisors Llc of Passage Bio at 0.68 subject to Rule 16b-3 | 01/08/2025 |
6 | Disposition of 126209 shares by Orbimed Advisors Llc of Passage Bio at 0.66 subject to Rule 16b-3 | 01/10/2025 |
7 | Disposition of 17986 shares by Orbimed Advisors Llc of Passage Bio at 0.64 subject to Rule 16b-3 | 01/13/2025 |
8 | Disposition of 79024 shares by Orbimed Advisors Llc of Passage Bio at 0.6 subject to Rule 16b-3 | 01/14/2025 |
9 | Acquisition by Sondhi Dolan of 48000 shares of Passage Bio at 0.848 subject to Rule 16b-3 | 01/24/2025 |
10 | Acquisition by Sondhi Dolan of 092 shares of Passage Bio at 1.28 subject to Rule 16b-3 | 01/31/2025 |
11 | Acquisition by Chou William of 575000 shares of Passage Bio at 1.5 subject to Rule 16b-3 | 02/06/2025 |
12 | Disposition of 12500 shares by Fotopoulos Alexandros of Passage Bio subject to Rule 16b-3 | 02/07/2025 |
13 | Disposition of 8000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3 | 02/10/2025 |
14 | Disposition of 3183 shares by Kathleen Borthwick of Passage Bio at 0.5296 subject to Rule 16b-3 | 02/11/2025 |
15 | Passage Bio GAAP EPS of -1.07 misses by 0.12 | 03/04/2025 |
16 | Passage Bio Releases Quarterly Earnings Results, Beats Estimates By 0.01 EPS | 03/05/2025 |
17 | Acquisition by Cale Edgar B. of 50000 shares of Passage Bio subject to Rule 16b-3 | 03/07/2025 |
18 | Acquisition by Cale Edgar B. of 278386 shares of Passage Bio at 0.387 subject to Rule 16b-3 | 03/14/2025 |
| Begin Period Cash Flow | 21.7 M |
Passage |
Passage Bio Relative Risk vs. Return Landscape
If you would invest 66.00 in Passage Bio on December 20, 2024 and sell it today you would lose (19.00) from holding Passage Bio or give up 28.79% of portfolio value over 90 days. Passage Bio is currently does not generate positive expected returns and assumes 7.7643% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than Passage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Passage Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Passage Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Passage Bio, and traders can use it to determine the average amount a Passage Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0407
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PASG |
Estimated Market Risk
| 7.76 actual daily | 69 69% of assets are less volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Passage Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Passage Bio by adding Passage Bio to a well-diversified portfolio.
Passage Bio Fundamentals Growth
Passage Stock prices reflect investors' perceptions of the future prospects and financial health of Passage Bio, and Passage Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Passage Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (26.23 M) | ||||
| Shares Outstanding | 62.15 M | ||||
| Price To Book | 0.41 X | ||||
| EBITDA | (70.4 M) | ||||
| Net Income | (64.77 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 25.48 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 0.99 X | ||||
| Cash Flow From Operations | (47.96 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 27.92 M | ||||
| Total Asset | 102.41 M | ||||
| Retained Earnings | (659.24 M) | ||||
| Working Capital | 59.45 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
About Passage Bio Performance
By analyzing Passage Bio's fundamental ratios, stakeholders can gain valuable insights into Passage Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Passage Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Passage Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.85) | (0.89) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (1.06) | (1.00) |
Things to note about Passage Bio performance evaluation
Checking the ongoing alerts about Passage Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Passage Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Passage Bio generated a negative expected return over the last 90 days | |
| Passage Bio has high historical volatility and very poor performance | |
| Passage Bio has some characteristics of a very speculative penny stock | |
| Passage Bio has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (64.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Passage Bio currently holds about 239.25 M in cash with (47.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Passage Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Passage Bio Releases Quarterly Earnings Results, Beats Estimates By 0.01 EPS |
- Analyzing Passage Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Passage Bio's stock is overvalued or undervalued compared to its peers.
- Examining Passage Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Passage Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Passage Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Passage Bio's stock. These opinions can provide insight into Passage Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |